Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study

J Interferon Res. 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531.


Fourteen evaluable patients with diffuse malignant mesothelioma were treated with a once-a-day for 5 days out of 7 for 6 weeks regimen of recombinant interferon-beta (IFN-beta ser). No responses were noted. The major toxicities included fever, chills, nausea, vomiting, and anorexia. IFN-beta ser at this dose and schedule does not appear to be an active single agent for patients with refractory malignant mesothelioma.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Drug Evaluation
  • Female
  • Humans
  • Interferon Type I / adverse effects
  • Interferon Type I / therapeutic use*
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-beta*
  • Male
  • Mesothelioma / drug therapy*
  • Middle Aged
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use


  • Interferon Type I
  • Recombinant Proteins
  • Interferon beta-1b
  • Interferon-beta
  • Interferon beta-1a